GAIN THERAPEUTICS, INC Long-Term Debt, Maturity, after Year Five
GAIN THERAPEUTICS, INC (GANX) had Long-Term Debt, Maturity, after Year Five of $68.90 thousand as of 2023-12-31, per its 10-K filed 2024-03-26.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive · last filed 2024-03-26
- 2023-12-31: Long-Term Debt, Maturity, after Year Five $68.90K.
- 2022-12-31: Long-Term Debt, Maturity, after Year Five $149.23K.
- 2022-03-31: Long-Term Debt, Maturity, after Year Five $214.39K.
- 2021-12-31: Long-Term Debt, Maturity, after Year Five $239.24K.
| Period end | Long-Term Debt, Maturity, after Year Five |
|---|---|
| 2023-12-31 | $68.90K 10-K · filed 2024-03-26 |
| 2022-12-31 | $149.23K 10-K · filed 2023-03-23 |
| 2022-03-31 | $214.39K 10-Q · filed 2022-05-16 |
| 2021-12-31 | $239.24K 10-K · filed 2022-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B |